NO990949L - Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS - Google Patents

Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS

Info

Publication number
NO990949L
NO990949L NO990949A NO990949A NO990949L NO 990949 L NO990949 L NO 990949L NO 990949 A NO990949 A NO 990949A NO 990949 A NO990949 A NO 990949A NO 990949 L NO990949 L NO 990949L
Authority
NO
Norway
Prior art keywords
aids
medicament
manufacture
treatment
pkc inhibitors
Prior art date
Application number
NO990949A
Other languages
English (en)
Norwegian (no)
Other versions
NO990949D0 (no
Inventor
Michael R Jirousek
Douglas K Ways
Lawrence E Stramm
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO990949D0 publication Critical patent/NO990949D0/no
Publication of NO990949L publication Critical patent/NO990949L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO990949A 1996-08-30 1999-02-26 Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS NO990949L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2487396P 1996-08-30 1996-08-30
US08/917,033 US6107327A (en) 1996-08-30 1997-08-26 Therapeutic treatment for HIV infection
PCT/US1997/015525 WO1998008509A1 (en) 1996-08-30 1997-08-28 Use of pkc inhibitors for the manufacture of a medicament for the treatment of aids

Publications (2)

Publication Number Publication Date
NO990949D0 NO990949D0 (no) 1999-02-26
NO990949L true NO990949L (no) 1999-02-26

Family

ID=26698971

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990949A NO990949L (no) 1996-08-30 1999-02-26 Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS

Country Status (15)

Country Link
US (1) US6107327A (cs)
EP (1) EP0830860A1 (cs)
JP (1) JP2002514177A (cs)
KR (1) KR20000035861A (cs)
CN (1) CN1228696A (cs)
AU (1) AU4179497A (cs)
BR (1) BR9711329A (cs)
CA (1) CA2263133A1 (cs)
CZ (1) CZ52099A3 (cs)
EA (1) EA199900245A1 (cs)
HU (1) HUP0002531A2 (cs)
IL (1) IL128107A0 (cs)
NO (1) NO990949L (cs)
PL (1) PL331760A1 (cs)
WO (1) WO1998008509A1 (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291446B1 (en) * 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US20020107193A1 (en) * 2000-11-09 2002-08-08 Glazner Gordon W. Therapeutic uses for IP3 receptor-mediated calcium channel modulators
JP2003327536A (ja) * 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
PH27309A (en) * 1989-11-13 1993-05-28 Merrell Dow Pharma Prevention of glycoprotein enveloped virus infectivity by quinolyl-and isoquinolyloxazone-2-ones
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
WO1995005824A1 (en) * 1993-08-24 1995-03-02 Smithkline Beecham Corporation Aaptamines and method of use thereof
BR9404830A (pt) * 1993-12-07 1995-08-08 Lilly Co Eli Composto e processo para sua preparação
KR100340159B1 (ko) * 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
AU4179497A (en) 1998-03-19
PL331760A1 (en) 1999-08-02
CZ52099A3 (cs) 1999-10-13
CN1228696A (zh) 1999-09-15
CA2263133A1 (en) 1998-03-05
BR9711329A (pt) 1999-08-17
IL128107A0 (en) 1999-11-30
JP2002514177A (ja) 2002-05-14
NO990949D0 (no) 1999-02-26
KR20000035861A (ko) 2000-06-26
EA199900245A1 (ru) 1999-08-26
EP0830860A1 (en) 1998-03-25
WO1998008509A1 (en) 1998-03-05
US6107327A (en) 2000-08-22
HUP0002531A2 (hu) 2001-02-28

Similar Documents

Publication Publication Date Title
NZ332563A (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
NO985066L (no) Terapeutisk behandling for VEGF-relaterte sykdommer
CA2253613A1 (en) Therapeutic treatment for vegf related occular diseases
ATE315933T1 (de) Therapeutische behandlung von kardiovaskularen krankheiten
EA199900987A1 (ru) Терапевтическое лечение заболеваний кожи
EA199900245A1 (ru) Использование ингибиторов протеинкиназы с для получения лекарственного препарата для лечения спида
EP0940141A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection
NZ334609A (en) Use of inhibitors of the beta isozyme of protein kinase C for treatment of sexual dysfunctions in mammals
EP0940142A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
EP0940143A3 (en) Use of PKC-inhibitors for the manufacture of a medicament for the treatment of asthma
NO990947L (no) Anvendelse av inhibitorer for PKC til fremstilling av et medikament for behandling av sentralnervesystemsykdommer forbundet med HIV-infeksjon
NO990948L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner
WO1999026609A3 (en) Therapeutic treatment for chronic myeloid leukemia and acute lymphoid leukemia
AU2450900A (en) Therapeutic nucleoside compound
DE69935881D1 (de) Bis-Indolylmaleimide zur therapeutischen Behandlung von Nieren-Funktionsstörungen
UY26735A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application